Glycans at the 'I' of the storm in humoral immunity and melanoma progression

Glycans at the 'I' of the storm in humoral immunity and melanoma progression
Charles J. Dimitroff, PhD, left, helps to train the next generation of immune/cancer research scientists. His laboratory is focused on the glyco-pathological basis of immunity, inflammation and cancer. Credit: Charles Dimitroff, Brigham and Women's Hospital

Two new studies have unveiled how a peculiar molecule impacts how antibody-producing cells develop and function as well as how normal melanocytes progress to melanoma malignancy.

"These findings on fundamental immunology and melanoma development originate from totally different areas of research, though have intersected at the bench," said Charles Dimitroff, Ph.D., of the Department of Dermatology at Brigham and Women's Hospital.

The Dimitroff lab, along with collaborators at Imperial College London, recently published two back-to-back-articles in the journal, Nature Communications, detailing novel findings on cell surface carbohydrates ('glycans') regulating human B cell function and human melanoma progression—two scientific areas seemingly at the opposite ends of the research spectrum.

Over a five-year period in the Dimitroff laboratory, Nicholas Giovannone, Ph.D., and Jenna Geddes Sweeney, Ph.D., who were investigating the global glycan features of human B at various stages of differentiation and of normal and malignant melanocytes, independently discovered that a distinct glycan feature known as blood group I-antigen or "I-branches" was remarkably central to glycan-mediated processes regulating both human B cell signaling/activation and melanoma aggressiveness. Precisely how these I-branch control B cell differentiation and humoral immunity or drive progression are still under intense investigation and likely to reveal new targets for immunomodulation or anti-cancer treatments.


Explore further

Discovery of four subtypes of melanoma points to new treatment approaches

More information: N. Giovannone et al, Galectin-9 suppresses B cell receptor signaling and is regulated by I-branching of N-glycans, Nature Communications (2018). DOI: 10.1038/s41467-018-05770-9
Provided by Brigham and Women's Hospital
Citation: Glycans at the 'I' of the storm in humoral immunity and melanoma progression (2018, August 22) retrieved 21 January 2019 from https://medicalxpress.com/news/2018-08-glycans-storm-humoral-immunity-melanoma.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more